Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Cumberland Pharmaceuticals is a Nashville-based specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products primarily in acute care hospital settings. The company operates a portfolio of FDA-approved products including Acetadote (acetylcysteine for acetaminophen overdose), Caldolor (ibuprofen injection for pain/fever), Kristalose (lactulose for constipation), and Vibativ (telavancin for hospital-acquired pneumonia). With an 82.6% gross margin but negative operating margins, the company faces profitability challenges despite maintaining hospital channel relationships.
Cumberland operates an asset-light model by acquiring rights to FDA-approved products with established safety profiles, then commercializing them through a specialized hospital sales force and distribution partnerships. The company avoids costly late-stage clinical development by focusing on approved products with niche hospital applications. Revenue comes from direct sales to hospitals, wholesalers, and specialty distributors. High gross margins (82.6%) reflect low manufacturing costs for established products, but significant SG&A expenses for maintaining hospital relationships and regulatory compliance drive negative operating margins. Pricing power is moderate, constrained by hospital formulary committees and GPO contracts.
Hospital utilization trends and acute care admission volumes, particularly for emergency/critical care where Acetadote and Caldolor are used
New product acquisitions or licensing deals that expand the portfolio without requiring clinical trials
Pricing actions or formulary wins at major hospital systems and GPO contracts
Path to profitability milestones - operating expense management and EBITDA breakeven timeline
Generic competition threats to key products or patent/exclusivity expirations
Hospital consolidation and GPO negotiating power continue to pressure specialty pharma pricing, with large health systems demanding deeper discounts and rebates that compress net realized prices
Shift toward value-based care and bundled payments may reduce hospital willingness to pay premium prices for branded acute care products when generic alternatives exist
FDA regulatory burden for maintaining legacy product approvals, including potential requirements for additional safety studies or manufacturing upgrades that strain limited resources
Generic competition for off-patent products in the portfolio, particularly as hospital pharmacies increasingly substitute generics even in acute care settings to control costs
Larger specialty pharma companies with broader portfolios and stronger hospital relationships can bundle products and offer better pricing, limiting Cumberland's ability to win formulary positions
Limited R&D capabilities mean the company cannot defend against competition through innovation or next-generation products
Negative operating cash flow and -17% operating margin create ongoing cash burn, with 1.23x current ratio suggesting limited liquidity cushion if revenue deteriorates
Small market cap ($100M) and negative profitability limit access to capital markets for growth investments or acquisitions, potentially forcing dilutive equity raises
Dependence on a small number of products means loss of exclusivity or formulary position for any key asset could materially impact the entire business
low - Hospital acute care demand is relatively non-discretionary and driven by medical emergencies rather than economic conditions. Acetaminophen overdoses, bacterial infections, and post-surgical pain occur regardless of GDP growth. However, hospital capital budgets and formulary decisions can be influenced by broader healthcare spending trends and reimbursement pressures during economic downturns.
Rising rates have moderate negative impact through two channels: (1) higher discount rates compress valuation multiples for unprofitable growth companies, particularly affecting small-cap biotech/pharma stocks, and (2) increased financing costs if the company needs to raise capital given negative cash flow. The 0.39 debt/equity ratio suggests manageable current debt levels, but future capital needs could be more expensive in a high-rate environment.
Moderate exposure to healthcare system credit conditions. Hospital financial stress can lead to slower payment cycles, increased pressure on pharmaceutical pricing, and more aggressive GPO negotiations. However, the acute care nature of Cumberland's products (emergency antidotes, critical infections) makes them less vulnerable to formulary cuts than elective-use medications.
value/turnaround - The 102.6% three-month return suggests recent speculative interest, possibly related to turnaround expectations or acquisition speculation. The negative profitability, small market cap, and established product portfolio attract value investors betting on operational improvements, cost cuts, or strategic alternatives. Not suitable for income investors (no dividend) or risk-averse growth investors given the cash burn. The stock likely appeals to small-cap specialists willing to accept illiquidity and turnaround execution risk.
high - Small-cap unprofitable specialty pharma stocks exhibit elevated volatility due to low float, limited analyst coverage, and binary outcomes around product performance, regulatory events, or strategic transactions. The 102.6% three-month surge followed by -20.1% one-year return demonstrates significant price swings typical of micro-cap healthcare names.
